Histone deacetylase 2 (HDAC2) regulates pathological response of inflammatory monocytes: a potential target of adjuvant therapies for COVID-19 infection 71SHARES Share via Pinterest Reddit Buffer Xing WhatsApp Flipboard Posted: 23 April 2020 | Dr Rosa Tordera (University of Navarra), Maria Cortes (University of Navarra) | No comments yet Histone deacetylase 2 (HDAC2) plays a key role in the regulation of inflammatory response in monocytes so could be a target for COVID-19, argue Dr Rosa Maria Tordera and Maria Cortes. Click here to download the research. With regular news updates and feature articles, our COVID-19 hub has everything you need to keep up to date with R&D during the pandemic. Click below to visit: COVID-19 hub Related topicsDrug Targets, Enzymes, Research & Development Related conditionsCoronavirus, Covid-19